AVAH · Aveanna Healthcare Holdings, Inc.
$13.16
+0.19 (+1.46%)
At close · Aug 21
Market Cap
$2.87B
Shares
218.22M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.16
Open$12.78
Day$12.39–13.61
52W close$6.22–13.16
Avg vol 30d2.9M
Short int4.4M · 2.0% float · 2.4d
Short vol22%
Last earningsAug 13, 2026
DataApr 2021–Aug 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Dec 3, 2026
Est · unconfirmed
· in 15 wks
FQ3-27 quarter ends
~Oct 1, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+61%
above
Price vs 50-day avg
+38%
above
RSI (14)
79
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+39%
trailing
6-month return
+77%
trailing
YTD return
+61%
this year
Relative strength
+66%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +54 funds added
Insider flow
Distributing
Net -$214.6M over 90 days · 100% sells
Short interest
Falling
2.02% of float · ▼ -2.2% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
212 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
Gross margin
33%
expanding
EPS growth
+1850%
Y/Y
Free cash flow
$109.9M
Valuation
P/E 10.4
below peers
Balance sheet
$1.1B
net debt
Quant / Vol
risk profile
Volatility
51%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 13, 2026
Revenue
· Full Year 2026
Initiated
at least $2.68B
prior FY $2.43B
midpoint +10.1% Y/Y
Adjusted EBITDA
· Full Year 2026
Non-GAAP
Initiated
at least $365M
Prior guidance
period ended
· from the 8-K filed Jan 14, 2026
Revenue
· full fiscal year 2025 (year ending January 3, 2026)
$2.43B – $2.45B
Adjusted EBITDA
· full fiscal year 2025 (year ending January 3, 2026)
$318M – $322M
Normalized Adjusted EBITDA
· full fiscal year 2025 (year ending January 3, 2026)
$298M – $302M
Guided vs delivered
· last 2 settled
Revenue
Full Year 2025
guided at least $2.38B
$2.43B
In line
Full year 2024 revenue
full year 2024
guided $2B
$2.02B
Beat +1.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+61%
Bullish
Price vs 50-day avg
+38%
Bullish
RSI (14)
79
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +54 funds added
Insider flow
Distributing
Net -$214.6M over 90 days · 100% sells
Short interest
Falling
2.02% of float · ▼ -2.2% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
212 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $13 · 100%
Range high $13
vs 200-day avg +61%
vs 50-day avg +38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $179.8M | Six-month period ended July 4, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP EBITDA 161.36M
+121K Goodwill, intangible and other long-lived asset impairment
+8.28M Non-cash share-based compensation
+1.5M Fees related to debt modifications
-6.17M Interest rate derivatives
+7.5M Acquisition-related costs
+2.67M Integration costs
+3.42M Legal costs and settlements associated with acquisition matters
+0K Restructuring
+28K Other legal matters
+1.08M Other adjustments
= Adjusted EBITDA 179.79M
|
|||
| Cost of revenue rate | $31.9 | six months ended July 4, 2026 | — |
| Field contribution non-GAAP | $231.08M | six months ended July 4, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Gross margin 423.95M
-192.87M Branch and regional administrative expenses
= Field contribution 231.08M
|
|||
| Free cash flow non-GAAP | $75.4M | Six-month period ended July 4, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operations 85.28M
-5.85M Purchases of property and equipment, and software
-3.31M Principal payments of term loans
-4.96M Principal payments of notes payable
+4.27M Settlements with swap counterparties
= Free cash flow 75.43M
|
|||
| Home health episodic admissions | 17.4K | six months ended July 4, 2026 | — |
|
|
|||
| Home health episodic mix | 80.9% | six months ended July 4, 2026 | — |
|
|
|||
| Home health revenue per completed episode | $3,185 | six months ended July 4, 2026 | — |
|
|
|||
| Home health total admissions | 21.5K | six months ended July 4, 2026 | — |
|
|
|||
| Home health total episodes | 29.6K | six months ended July 4, 2026 | — |
|
|
|||
| Hours | 24.47M | six months ended July 4, 2026 | — |
| Revenue rate | $44.53 | six months ended July 4, 2026 | — |
| Spread rate | $12.63 | six months ended July 4, 2026 | — |
| Unique patients served ("UPS") | 95K | Q2 FY2026 | — |
|
|
|||
| Adjusted net income non-GAAP | $40.36M | three-month period ended April 4, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income 41.65M
+3.32M Income tax expense
-24K Goodwill, intangible and other long-lived asset impairment
+4.15M Non-cash share-based compensation
-3.11M Interest rate derivatives
+3.11M Acquisition-related costs
+1.42M Integration costs
+2.06M Legal costs and settlements associated with acquisition matters
+0K Restructuring
+25K Other legal matters
+1.2M Other adjustments
-13.45M Income tax expense on adjusted pre-tax income
= Adjusted net income 40.36M
|
|||
| Adjusted net income per diluted share non-GAAP | $0.18 | three-month period ended April 4, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income per diluted share (GAAP) $0.19
+$0.05 Total adjustments
-$0.06 Income tax expense on adjusted pre-tax income
= Adjusted net income per diluted share $0.18
|
|||
| PDS Hours | 12.06M | three-month period ended April 4, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVAH
this stock
Aveanna Healthcare Holdings, Inc.
|
$2.87B | +61.1% | +20.2% | 10.4 | 2.0% |
|
HCA
HCA Healthcare, Inc.
|
$95.24B | -8.1% | +7.1% | 14.8 | 2.7% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.64B | -4.8% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.61B | +41.3% | +0.9% | 10.8 | 4.0% |
|
FMS
Fresenius Medical Care AG
|
$12.49B | -1.6% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVAH | +6.8% | +39.3% | +77.1% | +40.2% | +61.1% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +8.2% | +35.6% | +65.6% | +37.7% | +48.8% |
Key facts
CIK
1832332
CUSIP
05356F105
13F (30d)
196 filings
196 filers
Visit website
Investor relations